Tuberculosis (TB) is the leading opportunistic infection of people living with human immunodeficiency virus (HIV; PLWH). Cytochrome P450 (CYP) 2B6 and ATP-binding cassette sub-family B member 1 (ABCB1) are involved in the metabolism and transportation of efavirenz. The study was aimed to investigate the effects of rifampicin, CYP2B6 and ABCB1 polymorphisms on efavirenz exposure in Chinese PLWH co-infected with TB.
Method
PLWH were screened according to inclusion and exclusion criteria and divided into HIV group and HIV/TB group. Efavirenz plasma concentration (C0) was determined, dose-adjusted concentration (C0/D) was calculated, and genotypes of CYP2B6 516G>T, 785A>G, and ABCB1 2677G>T, 3435C>T were analyzed.
Results
252 PLWH were enrolled, including 75 co-infected with TB and concomitant with rifampicin. Efavirenz C0 and C0/D were both higher in HIV group (1.94 μg/mL, 0.2007 (μg/ml)/(mg/kg/d)) compared with HIV/TB group (1.52 μg/mL, 0.1557 (μg/ml)/(mg/kg/d)) (p = .001). Efavirenz C0/D was significantly higher in patients with variant genotypes of CYP2B6 516G>T and 785A>G (p<.001), and was significantly lower in HIV/TB group compared with HIV group among patients with CYP2B6 516 GG, TT, and 785 AA, AG genotypes (p < .05).
Conclusion
Efavirenz exposure is reduced by co-administration with rifampicin, and related to genetic polymorphisms of CYP2B6.
FordNMatteelliAShubberZ, et al.TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. J Int AIDS Soc2016; 19(1): 20714. DOI: 10.7448/ias.19.1.20714.
3.
NliwasaMMacPhersonPGupta-WrightA, et al.High HIV and active tuberculosis prevalence and increased mortality risk in adults with symptoms of TB: a systematic review and meta-analyses. J Int AIDS Soc2018; 21(7): e25162. DOI: 10.1002/jia2.25162.
YeWWuSChenY, et al.Clinical characteristics of HIV/AIDS patients with opportunistic infection different baseline levels of CD4+T cells receiving antireviral therapy. Chin J Nosocomiology2020; 30(15): 2296–2300. DOI: 10.11816/cn.ni.2020-192317.
6.
ZhaoHZhangLLiH, et al.Opportunistic infection in AIDS patients: clinical features, prognosis and its risk factors. Acad J Chin PLA Med Sch2021; 42(01): 45–47. DOI: 10.3969/j.issn.2095-5227.2021.01.010.
7.
LiuEWangQZhangG, et al.Tuberculosis/HIV coinfection and treatment trends - China, 2015-2019. China CDC Wkly2020; 2(48): 924–928. DOI: 10.46234/ccdcw2020.252.
8.
GandhiNMollALallooU, et al.Successful integration of tuberculosis and HIV treatment in rural South Africa: the Sizonq’oba study. J Acquir Immune Defic Syndr2009; 50(1): 37–43. DOI: 10.1097/QAI.0b013e31818ce6c4.
9.
Abdool KarimSNaidooKGroblerA, et al.Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med2011; 365(16): 1492–1501. DOI: 10.1056/NEJMoa1014181.
10.
LuetkemeyerARosenkranzSLuD, et al.Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS clinical trials group A5221 STRIDE study. Clin Infect Dis2013; 57(4): 586–593. DOI: 10.1093/cid/cit246.
Chinese Center for Disease Control and Prevention. Guidelines for AIDS diagnosis and treatment in China (2021 Edition). Chin J AIDS STD2021; 218(11): 1182–1201. DOI: 10.13419/j.cnki.aids.2021.11.02.
LiJMenardVBenishR, et al.Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment. Pharmacogenomics2012; 13(5): 555–570. DOI: 10.2217/pgs.11.160.
17.
NgaimisiEHabtewoldAMinziO, et al.Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. PLoS One2013; 8(7): e67946. DOI: 10.1371/journal.pone.0067946.
18.
De AlmeidaTDe AzevedoMPintoJ, et al.Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals. J Antimicrob Chemother2018; 73(9): 2460–2467. DOI: 10.1093/jac/dky190.
19.
MugusiSHabtewoldANgaimisiE, et al.Impact of population and pharmacogenetics variations on efavirenz pharmacokinetics and immunologic outcomes during anti-tuberculosis co-therapy: a parallel prospective cohort study in two sub-sahara African populations. Front Pharmacol2020; 11: 26. DOI: 10.3389/fphar.2020.00026.
20.
MukonzoJNanziguSWaakoP, et al.CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure. Pharmacogenomics2014; 15(11): 1423–1435. DOI: 10.2217/pgs.14.73.
21.
AurpibulLChotirosniramitNSugandhavesaP, et al.Correlation of CYP2B6-516G > T polymorphism with plasma efavirenz concentration and depression in HIV-infected adults in Northern Thailand. Curr HIV Res2012; 10(8): 653–660. DOI: 10.2174/157016212803901338
22.
GutiérrezFNavarroAPadillaS, et al.Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis2005; 41(11): 1648–1653. DOI: 10.1086/497835.
23.
YimerGAmogneWHabtewoldA, et al.High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J2012; 12(6): 499–506. DOI: 10.1038/tpj.2011.34.
24.
KappelhoffBVan LethFRobinsonP, et al.Are adverse events of nevirapine and efavirenz related to plasma concentrations?Antivir Ther2005; 10(4): 489–498.
25.
BensonEEadonMDestaZ, et al.Rifampin regulation of drug transporters gene expression and the association of microRNAs in human hepatocytes. Front Pharmacol2016; 7: 111. DOI: 10.3389/fphar.2016.00111.
26.
MarzoliniCTelentiADecosterdL, et al.Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS2001; 15(1): 71–75. DOI: 10.1097/00002030-200101050-00011.
27.
MukonzoJOkweraANakasujjaN, et al.Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC Infect Dis2013; 13: 261. DOI: 10.1186/1471-2334-13-261.
28.
UttayamakulSLikanonsakulSManosuthiW, et al.Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected thai adults. AIDS Res Ther2010; 7: 8. DOI: 10.1186/1742-6405-7-8.
29.
ManosuthiWSukasemCLueangniyomkulA, et al.Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. Antimicrob Agents Chemother2013; 57(2): 1019–1024. DOI: 10.1128/aac.02023-12.
30.
LeeKLinSSunH, et al.Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy. PLoS One2014; 9(2): e88497. DOI: 10.1371/journal.pone.0088497.
31.
LiuPFosterGLaBadieR, et al.Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. J Clin Pharmacol2008; 48(1): 73–84. DOI: 10.1177/0091270007309703.
32.
KaewpoowatQChaiwarithRYasriS, et al.Drug-drug interaction between itraconazole capsule and efavirenz in adults with HIV for talaromycosis treatment. J Antimicrob Chemother2021; 76(4): 1041–1045. DOI: 10.1093/jac/dkaa521.
33.
JiPDamleBXieJ, et al.Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. J Clin Pharmacol2008; 48(8):948–956. DOI: 10.1177/0091270008319792.
34.
KeublerAWeissJHaefeliW, et al.Drug interaction of efavirenz and midazolam: efavirenz activates the CYP3A-mediated midazolam 1’-hydroxylation in vitro. Drug Metab Dispos2012; 40(6): 1178–1182. DOI: 10.1124/dmd.111.043844.
35.
YinKMengXDongP, et al.A simple, rapid, economical, and practical method for the determination of efavirenz in plasma of Chinese AIDS patients by reverse phase high-performance liquid chromatography with ultraviolet detector. Biosci Trends2014; 8(4): 227–234. DOI: 10.5582/bst.2014.01002.
36.
GuoXYangYZhangB, et al.Nutrition and clinical manifestations of pulmonary tuberculosis: a cross-sectional study in Shandong province, China. Asia Pac J Clin Nutr2022; 31(1): 41–48. DOI: 10.6133/apjcn.202203_31(1).0005.
37.
CobelensFKerkhoffA. Tuberculosis and anemia-cause or effect?Environ Health Prev Med2021; 26(1): 93. DOI: 10.1186/s12199-021-01013-4.
38.
ImperialMNedelmanJConradieF, et al.Proposed linezolid dosing strategies to minimize adverse events for treatment of extensively drug-resistant tuberculosis. Clin Infect Dis2022; 74: 1736–1747. DOI: 10.1093/cid/ciab699.
39.
HuangSHuangWLinS, et al.Impact of efavirenz mid-dose plasma concentration on long-term weight change among virologically suppressed people living with HIV. J Acquir Immune Defic Syndr2021; 87(2): 834–841. DOI: 10.1097/qai.0000000000002650.
40.
GuoFChengXHsiehE, et al.Prospective plasma efavirenz concentration assessment in Chinese HIV-infected adults enrolled in a large multicentre study. HIV Med2018; 19: 440–451. DOI: 10.1111/hiv.12607.
41.
ChowNHarunSWongE, et al.The association between cigarette smoking and efavirenz plasma concentration using the population pharmacokinetic approach. Br J Clin Pharmacol2021; 87(10): 3756–3765. DOI: 10.1111/bcp.14783.
42.
Bordin AndriguettiNVan SchalkwykHBarrattD, et al.Large variability in plasma efavirenz concentration in papua new guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele. Clin Transl Sci2021; 14(6): 2521–2531. DOI: 10.1111/cts.13120.
43.
ChamnanphonMSukprasongRGaedigkA, et al.SULT1A1*2influence of polymorphism on plasma efavirenz concentration in thai HIV-1 patients. Pharmgenomics Pers Med2021; 14: 915–926. DOI: 10.2147/pgpm.s306358.
44.
SukasemCChamnanphonMKoomdeeN, et al.Pharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adults. Drug Metab Pharmacokinet2014; 29(4): 289–295. DOI: 10.2133/dmpk.dmpk-13-rg-077.
45.
ChalaATadesseBChakaT, et al.Predictors of efavirenz plasma exposure, auto-induction profile, and effect of pharmacogenetic variations among HIV-infected children in ethiopia: a prospective cohort study. J Pers Med2021; 11(12). DOI: 10.3390/jpm11121303.
46.
DestaZGammalRGongL, et al.Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2B6 and efavirenz-containing antiretroviral therapy. Clin Pharmacol Ther2019; 106(4): 726–733. DOI: 10.1002/cpt.1477.
47.
GuanSHuangMLiX, et al.Intra- and inter-ethnic differences in the allele frequencies of cytochrome P450 2B6 gene in Chinese. Pharm Res2006; 23(9): 1983–1990. DOI: 10.1007/s11095-006-9083-5.
48.
ToKLiuSCheungS, et al.Pharmacokinetics of plasma efavirenz and CYP2B6 polymorphism in southern Chinese. Ther Drug Monit2009; 31(4): 527–530. DOI: 10.1097/FTD.0b013e3181ad74a4.
49.
XuBGuoLLeeS, et al.Genetic variability of CYP2B6 polymorphisms in four southern Chinese populations. World J Gastroenterol2007; 13(14):2100–2103. doi:10.3748/wjg.v13.i14.2100.
50.
GaoLLiuFYangL, et al.The P450 oxidoreductase (POR) rs2868177 and cytochrome P450 (CYP) 2B6*6 polymorphisms contribute to the interindividual variability in human CYP2B6 activity. Eur J Clin Pharmacol2016; 72(10): 1205–1213. DOI: 10.1007/s00228-016-2095-0.
51.
GrieselRMaartensGChirehwaM, et al.CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. Clin Infect Dis2021; 73(11): e3902–e3909. DOI: 10.1093/cid/ciaa1073.
52.
DhoroMZvadaSNgaraB, et al.CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe. BMC Pharmacol Toxicol2015; 16:4. DOI: 10.1186/s40360-015-0004-2.
53.
ZakeriSAmiriNPirahmadiS, et al.Genetic variability of CYP2B6 polymorphisms in southeast Iranian population: implications for malaria and HIV/AIDS treatment. Arch Iran Med2014; 17(10): 685–691.
54.
ChenJSunJMaQ, et al.CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients. Ther Drug Monit2010; 32(5): 573–578. DOI: 10.1097/FTD.0b013e3181ea953c.
55.
UttayamakulSLikanonsakulSManosuthiW, et al.Influence of ABCB-1 C3435T polymorphisms on plasma nevirapine and efavirenz levels and their effects on virologic and immunological outcomes in HIV/TB co-infected Thai adults under anti-retroviral therapy. Southeast Asian J Trop Med Public Health2012; 43(1): 78–88.
56.
HaasDRibaudoHKimR, et al.Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS clinical trials group study. AIDS2004; 18(18): 2391–2400.
57.
MahunguTNairDSmithC, et al.The relationships of ABCB1 3435C>T and CYP2B6 516G>T with high-density lipoprotein cholesterol in HIV-infected patients receiving Efavirenz. Clin Pharmacol Ther2009; 86(2): 204–211. DOI: 10.1038/clpt.2009.78.
58.
HeilSvan der EndeMSchenkP, et al.Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals. Ther Drug Monit2012; 34(2): 153–159. DOI: 10.1097/FTD.0b013e31824868f3.
59.
ElensLVandercamBYombiJ, et al.Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics2010; 11(9): 1223–1234. DOI: 10.2217/pgs.10.94.
60.
GengiahTHolfordNBothaJ, et al.The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. Eur J Clin Pharmacol2012; 68(5): 689–695. DOI: 10.1007/s00228-011-1166-5.
61.
LuetkemeyerARosenkranzSLuD, et al.Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. Clin Infect Dis2015; 60(12): 1860–1863. DOI: 10.1093/cid/civ155.
62.
CerroneMWangXNearyM, et al.Pharmacokinetics of efavirenz 400 mg once daily coadministered with isoniazid and rifampicin in human immunodeficiency virus-infected individuals. Clin Infect Dis2019; 68(3): 446–452. DOI: 10.1093/cid/ciy491.
63.
AtwineDBonnetMTaburetA. Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review. Br J Clin Pharmacol2018; 84(8): 1641–1658. DOI: 10.1111/bcp.13600.
64.
ManosuthiWSukasemCThongyenS, et al.CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1. Antimicrob Agents Chemother2014; 58(4): 2268–2273. DOI: 10.1128/aac.02384-13.
65.
KitabiEMinziOMugusiS, et al.Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype. Sci Rep2018; 8(1): 16316. DOI: 10.1038/s41598-018-34674-3.
